David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Rafat Abonour, MD, of Indiana University Simon Cancer Center, discuss the session that he chaired on the question of whether researchers can design therapy that addresses the heterogeneity of the disease and eradicate most if not all of the myeloma clones.

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

Leukemia

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abstract on venetoclax monotherapy and deep remissions in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion (Abstract LBA6).

Leukemia

Lymphoma

Sagar Lonial, MD, and Alessandra Tedeschi, MD

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).

Lymphoma

Craig H. Moskowitz, MD

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Sep

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

What Constitutes Clinical Expertise in an AI-Enabled Era

NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera